Barriers and opportunities in pancreatic cancer immunotherapy

Pancreatic ductal adenocarcinoma (PDAC) presents a fatal clinical challenge characterized by a dismal 5-year overall survival rate, primarily due to the lack of early diagnosis and limited therapeutic efficacy. Immunotherapy, a proven success in multiple cancers, has yet to demonstrate significant benefits in PDAC. Recent studies have revealed the immunosuppressive characteristics of the PDAC tumor microenvironment (TME), including immune cells with suppressive properties, desmoplastic stroma, microbiome influences, and PDAC-specific signaling pathways. In this article, we review recent advances in understanding the immunosuppressive TME of PDAC, TME differences among various mouse models of pancreatic cancer,…

• AC
  American Cancer Society

  Award: DBG-22-161-01-MM
• HC
  Health Commission of Hubei Province
• NS
  Natural Science Foundation of Hubei Province
• WU
  Wuhan University
• HA
  Huazhong Agricultural University
• ZH
  Zhongnan Hospital of Wuhan University
• NI
  National Institutes of Health

  Awards: R01CA269140, R01CA166051
• UO
  University of Texas MD Anderson Cancer Center
• FR
  Fundamental Research Funds for the Central Universities